Killing of Glioblastoma

There is significant current interest in identifying new combination therapies that synergize to treat disease, and it is becoming increasingly clear that the temporal resolution of their administration greatly impacts efficacy.

To facilitate effective delivery, researchers in the Schneider Lab, as published in Angewandte Chemie, developed a multicompartment hydrogel material that is composed of spherical vesicles interlaced within a self‐assembled peptide‐based network of physically crosslinked fibrils that allows time‐resolved independent co‐delivery of small molecules.

This material architecture effectively delivers the EGFR kinase inhibitor Erlotinib, ERL, and Doxorubicin, DOX, DNA intercalator, in an ERL→DOX sequential manner to synergistically kill glioblastoma, the most aggressive form of brain cancer.

Design of a Multicompartment Hydrogel that Facilitates Time‐Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma
Poulami Majumder, Ulrich Baxa, Scott T. R. Walsh, Joel P. Schneider
Angewandte Chemie, Volume 57, Issue 46, November 12, 2018, Pages 15040-15044